Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Sep;24(9):1473-1474.
doi: 10.1038/cdd.2017.97. Epub 2017 Jun 16.

Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'

Daniel J Murphy  1 , Kevin G Blyth  2   3
Affiliations
Comment

Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'

Daniel J Murphy et al. Cell Death Differ. 2017 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Distinct tumour sub-populations are characterised by the spectrum of mutations present: mutations common to all regions are classed as clonal, whereas those present in a subset of regions are classed as subclonal. Shedding of detectable ctDNA from different tumour regions into circulation is correlated to the volume of the tumour subclone. Clonal mutations are more likely to be detected than subclonal mutations.
See this image and copyright information in PMC

Comment on

  • Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
    Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium; Swanton C. Abbosh C, et al. Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Nature. 2017. PMID: 28445469 Free PMC article.

References

    1. Pignon JP et al. J Clin Oncol 2008; 26: 3552–3559. - PubMed
    1. NICE Clinical Guidelines. 2011 Update. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22855970. Accessed date May 2017.
    1. Abbosh C et al. Nature 2017. (in press).
    1. Jamal-Hanjani M et al. PLoS Biol 2014; 12: e1001906. - PMC - PubMed
    1. Wan JC et al. Nat Rev Cancer 2017; 17: 223–238. - PubMed

Substances